The estimated absolute risks for pancreatic cancer in ATM PTV carriers (11% in males and 8% in females by age 85) are notably higher than for other major pancreatic susceptibility genes including BRCA2, CDK2NA, and PALB2, although the confidence limits are wide. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.